The molecular landscape of prostate cancer is discussed, before providing a detailed overview of the molecular approaches available for early detection and prognostication and highlighting areas of future research.
Abstract
Prostate cancer is the second-highest cause of cancer-related incidence and the fifth-highest cause of cancer mortality in males. Prostate cancer is a heterogeneous disease with a wide spectrum of clinical behaviour, ranging from indolent to highly aggressive. Molecular approaches, such as genomic testing, can augment existing clinical risk stratifications and tailor management to the individual. Genomic tests that sample biopsy or surgical tissue can provide a molecular risk assessment and identify actionable therapy targets. Liquid biopsy, while still emerging, may provide a non-invasive alternative to tissue tests and enable longitudinal monitoring of tumour status. We first discuss the molecular landscape of prostate cancer, before providing a detailed overview of the molecular approaches available for early detection and prognostication. Furthermore, methodological considerations and barriers towards clinical implementation for these tests are discussed, highlighting areas of future research.
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy among men in the United States and remains a leading cause of cancer-related mortality. Its marked biological, molecular, and histopathological heterogeneity creates a central diagnostic challenge: identifying clinically significant disease while l...
Abstract Background Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and continues to have poor survival outcomes, with most patients diagnosed at advanced stages of disease. In New Zealand, NSCLC contributes substantially to cancer inequities, with Māori communities experie...
Rajiv Kumar, Safia May Farry, Mark Ezegbogu et al.· JMIR Research Protocols· 0 citations
The current evidence on the clinical applications of circulating tumor DNA in muscle-invasive bladder cancer is summarized, including its role in prognosis, treatment selection, and surveillance, and future perspectives for integrating molecular monitoring into personalized cancer care are discussed.
M. Polito, L. Sisca, D. Caruso et al.· Cancers· 0 citations
This review summarizes the most promising biomarkers currently being investigated in metastatic colorectal cancer, including those measured in tumor tissue and those detected through blood-based tests, as well as emerging metabolic and lipid-related signatures.
E. Benidovskaya, N. Huyghe, M. V. Giolito et al.· Cancers· 0 citations
Simple Summary Colorectal cancer is no longer considered a single disease but rather a collection of biologically distinct tumor subtypes characterized by specific genetic alterations. These molecular differences have transformed patient management by enabling personalized treatment strategies based on individual tumor...
C. Macrea, Tiberia Ilias, Alexandra Costea et al.· Cancers· 1 citation
Colorectal cancer (CRC) remains a leading cause of global cancer mortality, underscoring the urgent need for effective early detection. Current screening methods, primarily colonoscopy, are limited by invasiveness and low population adherence, while traditional serological biomarkers lack sufficient sensitivity and spe...
Xiaoman Bai, Sa-Chu-La Bao, Xu-Qian Zhang et al.· World Journal of Gastrointes...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
